![](/assets/images/TRDizinlogo.png)
Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer
Yıl: 2022 Cilt: 37 Sayı: 2 Sayfa Aralığı: 115 - 121 Metin Dili: İngilizce DOI: 10.5505/tjo.2022.3335 İndeks Tarihi: 01-11-2022
Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer
Öz: OBJECTIVE This study aimed to evaluate the difference between serum levels of S100B and HSP70 in the non-meta- static, Luminal A breast cancer (BC) patients with the healthy population, and determine the impact of post-operative radiotherapy (RT) on serum markers. METHODS 21 BC patients who underwent chest wall/breast±axillary RT after adjuvant chemotherapy and twenty- one healthy individuals were included in the study group. The changes in serum HSP70 and S100B levels were observed in the study and control groups. RESULTS A total of 42 participants were included. A significant difference was found between the HSP70 and S100B measurements of the study and control groups before and after RT (P=0.001 and p<0.01, re- spectively). At the same time, the increase in HSP70 after RT was statistically significant (p=0.025 and p<0.05, respectively). However, the change in S100B measurements after RT was not statistically signifi- cant in the study group patients compared to before RT (p>0.627). CONCLUSION S100B and HSP70 levels are higher than the healthy population before and after RT in non-metastatic, luminal A BC patients. The significant increase in Hsp70 after RT may be due to the release from dying tumor cells in the microenvironment. Therefore, HSP70 levels in the blood may be useful for micro- scopic tumor focus detection or evaluation of treatment response.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Ahmad A. Breast Cancer Statistics: Recent Trends. Adv Exp Med Biol 2019;1152:1–7.
- 2. Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS. Effects of multidisciplinary team work- ing on breast cancer survival: retrospective, compar- ative, interventional cohort study of 13 722 women. BMJ 2012;344:e2718.
- 3. Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fi- etkau R, et al. Current controversies in RT for breast cancer. Radiat Oncol 2017;12:25.
- 4. Jagsi R. Progress and controversies: radiation ther- apy for invasive breast cancer. CA Cancer J Clin 2014;64(2):135–52.
- 5. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, et al; American Society of Clin- ical Oncology. Breast cancer follow-up and manage- ment after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31(7):961–5.
- 6. Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol 2016;34(9):927.
- 7. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008;100(16):1179.
- 8. Soysal SD, Tzankov A, Muenst SE. Role of the Tumor Microenvironment in Breast Cancer. Pathobiology 2015;82(3–4):142–52.
- 9. Coleman RE, Gregory W, Marshall H, Wilson C, Holen I. The metastatic microenvironment of breast cancer: clinical implications. Breast 2013;22(suppl 2):50–6.
- 10. Harpio R, Einarsson R. S100 proteins as can- cer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004;37(7):512–8.
- 11. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tu- morigenesis. Trends Biochem Sci 2006;31(3):164–72.
- 12. Straume O, Shimamura T, Lampa MJ, Carretero J, Øyan AM, Jia D, et al. Suppression of heat shock pro- tein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A 2012;109(22):8699– 704.
- 13. Yun CW, Kim HJ, Lim JH, Lee SH. heat shock proteins: agents of cancer development and therapeutic targets in anti-cancer therapy. Cells 2019;9(1):60.
- 14. Bentzen SM, Parliament M, Deasy JO, Dicker A, Cur- ran WJ, Williams JP, et al. Biomarkers and surrogate endpoints for normal-tissue effects of radiation ther- apy: the importance of dose-volume effects. Int J Ra- diat Oncol Biol Phys 2010;76(3 Suppl):S145–50.
- 15. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965;19(6):739–44.
- 16. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003;14(7):1072–7.
- 17. Weide B, Richter S, Büttner P, Leiter U, Forschner A, Bauer J, et al. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. Plos One 2013;8(11):e81624.
- 18. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, We- ber DJ, et al. Functions of S100 proteins. Curr Mol Med 2013;13(1):24–57.
- 19. Romner B, Ingebrigtsen T, Kongstad P, Børgesen SE. Traumatic brain damage: serum S-100 protein mea- surements related to neuroradiological findings. J Neurotrauma 2000;17(8):641–7.
- 20. Charmsaz S, Hughes E, Bane FT, Tibbitts P, McIlroy M, Byrne C, et al. S100B as a serum marker in endocrine resistant breast cancer. BMC Medicine 2017;15:79.
- 21. Sherman M. Major heat shock protein Hsp72 controls oncogene-induced senescence. Ann N Y Acad Sci 2010;1197:152–7.
- 22. Calderwood SK, Gong J. Heat Shock Proteins Promote Cancer: It’s a Protection Racket. Trends Biochem Sci 2016;41(4):311–23.
- 23. Joly AL, Wettstein G, Mignot G, Ghiringhelli F, Gar- rido C. Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J Innate Immun 2010;2(3):238–47.
- 24. Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S. Heat shock proteins and cancer. Trends Pharmacol Sci 2017;38(3):226–56.
- 25. Ishibashi J, Yamashita K, Ishikawa T, Hosokawa H, Sumida K, Nagayama M, et al. The effects inhibiting the proliferation of cancer cells by far-infrared radi- ation (FIR) are controlled by the basal expression level of heat shock protein (HSP) 70A. Med Oncol 2008;25(2):229–37.
- 26. Jagadish N, Agarwal S, Gupta N, Fatima R, Devi S, Kumar V, et al. Heat shock protein 70-2 (HSP70-2) overexpression in breast cancer. J Exp Clin Cancer Res 2016;35(1):150.
- 27. Hurwitz MD, Kaur P, Nagaraja GM, Bausero MA, Manola J, Asea A. Radiation therapy induces circu- lating serum Hsp72 in patients with prostate cancer. Radiother Oncol 2010;95:350–8.
- 28. Gehrmann M, Specht HM, Bayer C, Brandstetter M, Chizzali B, Duma M, et al. Hsp70--a biomarker for tu- mor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck. Radiat Oncol 2014;9:131.
APA | Ozer e, Isiksacan N, Soydemir G, Sahingoz Erdal G, Gedikbasi A, Kırlı M (2022). Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer. , 115 - 121. 10.5505/tjo.2022.3335 |
Chicago | Ozer elif eda,Isiksacan Nilgun,Soydemir Gülşen Pınar,Sahingoz Erdal Gulcin,Gedikbasi Asuman,Kırlı Meltem Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer. (2022): 115 - 121. 10.5505/tjo.2022.3335 |
MLA | Ozer elif eda,Isiksacan Nilgun,Soydemir Gülşen Pınar,Sahingoz Erdal Gulcin,Gedikbasi Asuman,Kırlı Meltem Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer. , 2022, ss.115 - 121. 10.5505/tjo.2022.3335 |
AMA | Ozer e,Isiksacan N,Soydemir G,Sahingoz Erdal G,Gedikbasi A,Kırlı M Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer. . 2022; 115 - 121. 10.5505/tjo.2022.3335 |
Vancouver | Ozer e,Isiksacan N,Soydemir G,Sahingoz Erdal G,Gedikbasi A,Kırlı M Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer. . 2022; 115 - 121. 10.5505/tjo.2022.3335 |
IEEE | Ozer e,Isiksacan N,Soydemir G,Sahingoz Erdal G,Gedikbasi A,Kırlı M "Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer." , ss.115 - 121, 2022. 10.5505/tjo.2022.3335 |
ISNAD | Ozer, elif eda vd. "Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer". (2022), 115-121. https://doi.org/10.5505/tjo.2022.3335 |
APA | Ozer e, Isiksacan N, Soydemir G, Sahingoz Erdal G, Gedikbasi A, Kırlı M (2022). Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer. Türk Onkoloji Dergisi, 37(2), 115 - 121. 10.5505/tjo.2022.3335 |
Chicago | Ozer elif eda,Isiksacan Nilgun,Soydemir Gülşen Pınar,Sahingoz Erdal Gulcin,Gedikbasi Asuman,Kırlı Meltem Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer. Türk Onkoloji Dergisi 37, no.2 (2022): 115 - 121. 10.5505/tjo.2022.3335 |
MLA | Ozer elif eda,Isiksacan Nilgun,Soydemir Gülşen Pınar,Sahingoz Erdal Gulcin,Gedikbasi Asuman,Kırlı Meltem Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer. Türk Onkoloji Dergisi, vol.37, no.2, 2022, ss.115 - 121. 10.5505/tjo.2022.3335 |
AMA | Ozer e,Isiksacan N,Soydemir G,Sahingoz Erdal G,Gedikbasi A,Kırlı M Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer. Türk Onkoloji Dergisi. 2022; 37(2): 115 - 121. 10.5505/tjo.2022.3335 |
Vancouver | Ozer e,Isiksacan N,Soydemir G,Sahingoz Erdal G,Gedikbasi A,Kırlı M Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer. Türk Onkoloji Dergisi. 2022; 37(2): 115 - 121. 10.5505/tjo.2022.3335 |
IEEE | Ozer e,Isiksacan N,Soydemir G,Sahingoz Erdal G,Gedikbasi A,Kırlı M "Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer." Türk Onkoloji Dergisi, 37, ss.115 - 121, 2022. 10.5505/tjo.2022.3335 |
ISNAD | Ozer, elif eda vd. "Early Effect of Radiotherapy on Serum Levels of HSP70 and S100B in Patients with Breast Cancer". Türk Onkoloji Dergisi 37/2 (2022), 115-121. https://doi.org/10.5505/tjo.2022.3335 |